Bristol Myers Squibb Buys Turning Point for US$4.1 B
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)
Published: 8 Jun-2022
DOI: 10.3833/pdr.v2022.i6.2695 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In an attempt to bolster its oncology portfolio, Bristol Myers Squibb (BMS) has entered into an agreement to acquire Turning Point Therapeutics for US$76 per share...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS